PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Phase 2

Withdrawn

Conditions: Kidney Transplantation

Interventions: Drug: Cyclosporine
Drug: CP-690-,550

First Posted Date: 2007-11-09

Last Posted Date: 2008-05-30

Lead Sponsor: Pfizer

Registration Number: NCT00556257

Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: 5-fluorouracil
Drug: cisplatin
Drug: sunitinib malate

First Posted Date: 2007-11-09

Last Posted Date: 2011-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT00555672

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: PD 0332991

First Posted Date: 2007-11-09

Last Posted Date: 2015-03-19

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT00555906

Locations: 🇺🇸
University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇺🇸
Barnes-Jewish Hospital, St. Louis, Missouri, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

and more 15 locations

Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: capecitabine
Drug: oxaliplatin
Drug: cisplatin
Drug: sunitinib malate

First Posted Date: 2007-11-08

Last Posted Date: 2013-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT00555620

Locations: 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of

Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury

Phase 4

Terminated

Conditions: Brain Injuries
Growth Hormone Deficiency

Interventions: Drug: Genotropin
Drug: Placebo

First Posted Date: 2007-11-07

Last Posted Date: 2010-06-02

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT00555009

Locations: 🇬🇧
Pfizer Investigational Site, Salford, Manchester, United Kingdom

Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

Phase 1

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Cisplatin
Drug: S-1
Drug: Sunitinib

First Posted Date: 2007-11-04

Last Posted Date: 2015-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00553696

Locations: 🇯🇵
Saku Central Hospital, GI Devision, Saku, Nagano, Japan
🇯🇵
Aichi cancer center central hospital / Medical Oncology, Nagoya, Aichi, Japan
🇯🇵
Shizuoka Cancer Center, Suntougun, Shizuoka, Japan

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Drug: PF-00299804

First Posted Date: 2007-11-04

Last Posted Date: 2020-10-19

Lead Sponsor: Pfizer

Target Recruit Count: 55

Registration Number: NCT00553254

Locations: 🇰🇷
Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Department of Medicine, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea, Republic of

Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic

Phase 4

Completed

Conditions: Pain

Interventions: Drug: Ketoprofen 100mg
Drug: Parecoxib 40mg

First Posted Date: 2007-11-04

Last Posted Date: 2013-01-28

Lead Sponsor: Pfizer

Target Recruit Count: 340

Registration Number: NCT00553605

Locations: 🇵🇪
Pfizer Investigational Site, Lima, Peru

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

Phase 2

Completed

Conditions: Primary Insomnia

Interventions: Drug: PD 0200390
Other: Placebo

First Posted Date: 2007-10-30

Last Posted Date: 2012-07-25

Lead Sponsor: Pfizer

Target Recruit Count: 92

Registration Number: NCT00551148

Locations: 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: PD 0360324
Drug: Placebo

First Posted Date: 2007-10-29

Last Posted Date: 2009-07-14

Lead Sponsor: Pfizer

Target Recruit Count: 78

Registration Number: NCT00550355

Locations: 🇪🇸
Pfizer Investigational Site, Santiago de Compostela, A Coruña, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy